PMC:7796052 / 15596-15771 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"398","span":{"begin":68,"end":79},"obj":"Gene"},{"id":"399","span":{"begin":113,"end":123},"obj":"Gene"},{"id":"404","span":{"begin":20,"end":30},"obj":"Chemical"}],"attributes":[{"id":"A398","pred":"tao:has_database_id","subj":"398","obj":"Gene:624"},{"id":"A399","pred":"tao:has_database_id","subj":"399","obj":"Gene:3827"},{"id":"A404","pred":"tao:has_database_id","subj":"404","obj":"MESH:D020849"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Results showed that raloxifene is a weak partial agonist toward the B2 receptor, with a 19% efficacy compared to bradykinin, with an apparent dissociation constant KB ~ 21 µM."}

{"project":"LitCovid-sentences","denotations":[{"id":"T109","span":{"begin":0,"end":175},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Results showed that raloxifene is a weak partial agonist toward the B2 receptor, with a 19% efficacy compared to bradykinin, with an apparent dissociation constant KB ~ 21 µM."}